Qube Research & Technologies LTD Affimed N.V. Transaction History

Qube Research & Technologies LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.32 - $0.62 $5,664 - $10,975	-17,702 Reduced 87.46%	2,538 $1,000
Q3 2023 Nov 13, 2023	SELL	$0.46 - $0.65 $89,802 - $126,894	-195,223 Reduced 90.61%	20,240 $9,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.08 $122,813 - $232,700	215,463 New	215,463 $129,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $39,147 - $66,310	19,973 Added 125.25%	35,920 $74,000
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $36,199 - $77,502	15,947 New	15,947 $44,000
Q4 2021 Feb 01, 2022	SELL	$5.37 - $7.07 $345,151 - $454,417	-64,274 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $174,404 - $236,422	-31,481 Reduced 32.88%	64,274 $397,000
Q2 2021 Aug 13, 2021	BUY	$7.78 - $11.4 $321,135 - $470,557	41,277 Added 75.77%	95,755 $814,000
Q1 2021 May 14, 2021	BUY	$5.12 - $8.48 $98,831 - $163,689	19,303 Added 54.88%	54,478 $431,000
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $111,153 - $247,280	35,175 New	35,175 $205,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.